Roche has discontinued development of Dalcetrapib, an HDL-raising CETP inhibitor being studied in coronary heart disease, following the results of the second interim analysis of the dalcetrapib dal-OUTCOMES Phase III trial. An independent Data and Safety Monitoring Board (DSMB) recommended stopping the trial due to a lack of clinically meaningful efficacy. “Lowering cardiovascular risk beyond that which is achieved with intensive statin treatment is a very challenging goal and while we have alw...